Some innovative practices workshops instruct medical residents about the physical examination of the locomotor system.

● Residents of Orthopedic Surgery and Traumatology have had the opportunity to train in the physical form of current, complete and practical.
● The conference took place within the Congress of the Spanish Society of osteoporotic fractures


Under the Second Congress of the Spanish Society of osteoporotic fracture (SEFRAOS), which is taking place these days in Madrid, there have been some innovative practices Exploration Workshop Physics Locomotive. The purpose of these meetings has been to offer a comprehensive and detailed knowledge of the specific exercises necessary to address the problems of locomotion. As commented by Dr. Antonio Rios, Orthopedic Surgery Service, Hospital Virgen del Mar de Almería, who has been a teacher "It is essential for proper diagnosis of any problem locomotor conducting a thorough physical examination it. This is a test of a very high reliability and great tradition, to which is added a series of radiological tests in order to obtain an accurate diagnosis. "

At the conference, sponsored by Bayer Schering Pharma, residents have orthopedic surgery and traumatology in Spain. Professor Francisco Gomar has been in charge of coordinating the practices taught by specialists who have carried out spot tests for structured exploration location: shoulder, knee, spine, hip, hand, ankle-foot.

According to Dr. Rios' One day as we have given are of great importance for the learning of medical residents as it is rare to receive such training. " It added that "practices, in the framework of a national congress, are quite novel in Spain. But in the American Congress is very common and make small workshops, several hours' duration, which focus on a specific part of the locomotor system, and study from beginning to end everything associated with it. I trust that these meetings will be repeated next year in the Congress of the SEFRAOS to become a tradition. "


Roundtable on thromboembolic disease

Bayer Schering Pharma also sponsors of this Congress in a Roundtable on thromboembolic disease tomorrow.

During the meeting, national experts will address various aspects of thromboprophylaxis: the role of primary care, the use of catheters, new drugs, etc..

Referring to the issue of new drugs for the treatment of thromboembolic disease, the European Commission in September 2008 authorized the sale of Xarelto ® (rivaroxaban), a new anticoagulant, and fixed-dose oral administration once daily for preventing the formation of venous blood clots in patients undergoing elective surgery for total hip replacement and knee. Bayer Schering Pharma will market Xarelto ® in Spain shortly, a drug that has been launched in over 15 countries worldwide.

The marketing authorization by the European Union (EU), was received after the evaluation of data from the RECORD clinical program that included three Phase III studies conducted with rivaroxaban, involving nearly 10,000 patients undergoing elective surgery of replacing hip or knee (RECORD1, RECORD2 and RECORD3). The results of this program demonstrate the superior efficacy of rivaroxaban compared with enoxaparin in both tests (RECORD1 and RECORD3) as compared to the long pattern of rivaroxaban (5 weeks) compared to the standard short (2 weeks) enoxaparin (RECORD2). In all three studies, rivaroxaban showed a comparable safety profile, including a low incidence of bleeding similar.

Xarelto ® provides the comfort of administration in the hospital and home, as it does not require monitoring or dose adjustment. As an oral treatment, unlike conventional heparins are administered by injection, and low risk of interactions with other drugs, it makes has all the characteristics the ideal anticoagulant. Rivaroxaban offers superior performance, without an increased risk of bleeding.
The extensive program of clinical trials of the drug make it an oral anticoagulant, direct Factor Xa inhibitor, the world's most studied so far. It is expected that over 60,000 patients are included in the clinical development program for rivaroxaban, which will investigate the product for the prevention and treatment of a wide range of diseases, both acute and chronic, related to blood clotting. For example the treatment of venous thromboembolism (VTE), prevention of stroke in patients with atrial fibrillation, the prevention of VTE in medical patients in hospitals and secondary prevention of acute coronary syndrome.